Kornimate/medical-research-clean huggingface dataset:
effects of birth weight on anterior eye segment measurements in full-term children by galilei dual-scheimpflug analyzer

Conditions: Birth Weight

Summary: this study evaluates the effects of birth weight (bw) on ocular anterior segment parameters in preschool children using the galilei dual-sheimpflug analyzer (gd-sa). children were measured by gd-sa and relationships between all anterior segment parameters obtained by this device and birth weight were analyzed.

preschoolers, who were born heavier, had thicker cornea and lens, longer axial length, and flatter corneal curve. the thicknesses and axial curves of central cornea within 7mm may be particularly associated with bw.

Eligibility criteria:
inclusion criteria: * ages 3- 6 years; * birth weight \>2,500 g; * gestational age (i.e., the period of time between the first day of the mother's last menstrual period and birth) \>37 weeks; * visual acuity \>0.8 (in decimals); * no history of any systemic or ocular diseases; * no history of previous ocular surgeries; * no retinopathy of prematurity; * no current medications; and * no retinal or optic disc abnormalities on fundoscopy. exclusion criteria: * ages \ 6 years; * birth weight \<2,500 g; * gestational age (i.e., the period of time between the first day of the mother's last menstrual period and birth) \<37 weeks; * visual acuity \<0.8 (in decimals); * history of any systemic or ocular diseases; * history of previous ocular surgeries; * retinopathy of prematurity; * current medications; and * retinal or optic disc abnormalities on fundoscopy.
study for secondary hyperparathyroidism in chronic renal insufficiency patients

Conditions: Secondary Hyperparathyroidism; Chronic Renal Insufficiency

Summary: this study will assess an investigational medication for patients with chronic renal insufficiency (pre-dialysis) who have secondary hyperparathyroidism.


Eligibility criteria:
inclusion criteria: * patients must have chronic renal insufficiency (pre-dialysis) * have below normal creatinine clearance * have elevated parathyroid hormone levels exclusion criteria: * pregnant or nursing * heart attack in the last 3 months.
effects of home-based vs. clinic-based rehabilitation on sensorimotor, cognition, daily function, and participation

Conditions: Chronic Stroke

Summary: the purpose of this study was to compare the treatment effects of home-based or clinic-based bilateral training with and without mirror feedback programon on physiological markers, sensorimotor, cognition, daily functions, and participation among patients with chronic stroke.


Eligibility criteria:
inclusion criteria: * the most recent stroke was between 1 month and 5 years * no serious cognitive impairment (mmse≥21) * fma score =18-62 * no serious muscle spasticity in shoulder, elbow, wrist and finger (mas≤3) * modified rankin scale=2 to 4 exclusion criteria: * aphasia that might interfere with understanding instructions * stroke in areas other than the brain and brainstem, such as the cerebellum * other neurological disease, such as dementia * muscle and joint have serious pain and inflammatory swelling in affected side. * cannot control hypertension, heart disease and serious throbosis
intacs (intrastromal corneal ring segments) for corneal ectasia

Conditions: Keratoconus

Summary: to join established study put on by addition technologies, inc. in the surgical implantation of asymmetrical intacs segments to treat myopia and astigmatism in patients with keratoconus.

use of asymmetrical corneal inserts to reduce or eliminate myopia and astigmatism in patients with keratoconus, who are no longer able to achieve adequate vision with their contact lenses or spectacles, so that their functional vision may be restored and the need for corneal transplantation may potentially be deferred.

Eligibility criteria:
inclusion criteria: * 21 years of age, or older * have experienced a progressive deterioration in their vision, such that they can no longer achieve adequate functional vision on a daily basis with contact lenses, or spectacles. * have clear central corneas * have a corneal thickness of 450 microns or greater at the proposed incision site * have corneal transplantation as the only remaining option to improve their visual function exclusion criteria: * under 21 years of age * have not experienced a progressive deterioration in their vision, such that they can no longer achieve adequate functional vision on a daily basis with contact lenses, or spectacles. * do not have clear central corneas * do not have a corneal thickness of 450 microns or greater at the proposed incision site * do not have corneal transplantation as the only remaining option to improve their visual function
efficacy of wj-derived mesenchymal stem cells in combination with parathyroid hormone for vertebral compression fracture

Conditions: Vertebral Compression Fracture; Osteoporotic Fractures

Summary: osteoporotic vertebral compression fractures (ovcfs) are serious health problems. transplantation of mesenchymal stem cells (mscs) has gained considerable attention to treat osteoporosis and ovcfs because implanted healthy mscs could be differentiated into osteoblasts and reduce the susceptibility of fractures by facilitating new bone formation. this study compares teriparatide (pth 1-34) injection to combined treatment with wharton's jelly-derived mscs (wj-mscs) and teriparatide (pth 1-34) in patients with ovcfs. it is a randomized, open-label, phase 2 study.


Eligibility criteria:
inclusion criteria: * postmenopausal women over 40 years of age * compression fracture of the spine confirmed by mri or bone scan * when the t score of the lumbar spine is less than -1.0 in the bone density test using dxa (dual energy x ray absorptiometry) * compression fracture is between 5th thoracic and 5th lumbar vertebra * when a new vertebral fracture occurs in less than 3 parts of the spine * compression fracture of the spine within 6 weeks after minor trauma * oswestry disability index (odi) due to vertebral fracture is more than 30% * back pain due to vertebral fracture has a visual analogue scale (vas) of 4 or higher. * in case of writing consent for stem cell transplantation therapy exclusion criteria: * those who used osteoporosis treatment (bisphosphonate, selective estrogen receptor modulator, or parathyroid hormone) 6 months before the start of the clinical trial due to osteoporotic vertebral fracture. * in the case of inherited, metabolic, neoplastic, or infectious bone disease other than osteoporosis * spinal fracture with neurological symptoms * those who are taking drugs that affect bone metabolism such as steroids. * those who have undergone spinal fixation surgery on the fracture site prior to the clinical trial * those who have a history of psychiatry or who are currently undergoing treatment, who have judged that it is difficult to proceed with the clinical trial under the judgment of the researcher * those who do not understand the purpose and method of this clinical trial as a study subject for drug or alcohol addiction * those who participated in other clinical trials within 30 days prior to participation in the clinical trial * those who may affect this clinical trial due to serious medical conditions (hypertension not controlled by drugs, diabetes not controlled by drugs, blood coagulation disease, cirrhosis, kidney failure, tumor) or immune deficiency * factors less than 10 g/dl of hemoglobin in general blood test * if there is currently an acute systemic or local infection * others who have clinically significant findings deemed inappropriate for this clinical trial due to medical judgment by the person in charge of the clinical trial * those who are allergic to proteins required for cell production (fetal calf serum)

Keywords: vertebral compression fracture back pain
sleep apnea in frail elderly

Conditions: Ageing; Sleep Apnea

Summary: sleep apnea syndrome is common and increases with age. in the elderly, symptoms might be different than in the youngest people, and its consequences might be severe and atypical (falls, functional and cognitive decline). today, there is no specific tool to detect sleep apnea in the elderly. the goal of this study is to evaluate the accuracy of oximetry for detection of respiratory disturbances in sleep apnea in the hospitalized elderly.

main goal: to define the more specific and sensitive cut-off of variability index of the oximetry to detect sleep apnea in the hospitalized elderly. secondary goals: * sleep apnea prevalence in the elderly * accuracy of other oximetry parameters (saturation line, oximetry desaturation index, autonomic arousals) for detection of respiratory disturbances in sleep apnea in the hospitalized elderly * to determine the clinical and biological data associated with sleep apnea in the hospitalized elderly * to determine the factors associated with the record failures and its prevalence * to study the prevalence of the periodic limb movements of sleep in the hospitalized elderly study design: simultaneous records by oximetry and ventilatory polygraphy with tibial emg in the hospitalized elderly in a geriatric readaptation unit.

Eligibility criteria:
inclusion criteria: * age \> 75 ans * affiliation to the french health care system exclusion criteria: * hypoxemia with oxygenotherapy * already known and treated sleep apnea syndrome * mild to severe dementia (mmse\<18/30) * nocturnal neurpsychological disturbances * acute organic failure

Keywords: frail elderly hospitalized sleep apnea oximetry
a study of shr-a1811 in first-line treatment of patients with advanced or metastatic non-small cell lung cancer with her2 mutations

Conditions: Non-Small Cell Lung Cancer With HER2- Mutations

Summary: the study is being conducted to evaluate the efficacy, and safety of shr-a1811 versus standard of care as first-line treatment of advanced or metastatic non-small cell lung cancer with her2- mutations


Eligibility criteria:
inclusion criteria: 1. able and willing to provide a written informed consent 2. 18-75 years old (inclusive of both ends) 3. ecog score of 0 or 1. 4. patients with histologically or cytologically confirmed advanced or metastatic nsclc. 5. subjects with central laboratory- confirmed functional her2 mutations 6. no prior systemic antitumor therapy (including investigational agents) for advanced or metastatic nsclc. 7. have at least one measurable lesion outside the central nervous system that meets the criteria defined by recist v1.1 8. protocol-defined adequate organ function including cardiac, renal, hepatic function exclusion criteria: 1. mixed lung cancer with small cell components and sarcomatoid carcinoma confirmed by histology or cytology. 2. concurrently carrying other driver gene mutations, and targeted drugs for such driver gene mutations have been approved for market release. 3. subjects with untreated or active metastasis of central nervous system (cns) tumors, or a history of meningeal metastasis or current meningeal metastasis. 4. with poorly controlled tumor-related pain. 5. previous or current with other malignancies. 6. subjects with a history of interstitial pneumonia/non-infectious pneumonia requiring hormone therapy, or current interstitial pneumonia/non-infectious pneumonia. 7. subjects with active or previous autoimmune diseases. 8. subjects with uncontrolled or severe cardiovascular diseases. 9. subjects with active hepatitis b or hepatitis c.
role of 3 tesla diffusion weighted magnetic resonance imaging (dw-mri) for diagnosis bladder cancer grade and stage

Conditions: Bladder Cancer; Diagnoses Disease; Magnetic Resonance Imaging; Apparent Diffusion Coefficient

Summary: assess diagnostic performance of 3-tesla dw-mri in detecting and staging bladder cancer and potential role of the adc value as a biomarker reflecting histological grade and stage.


Eligibility criteria:
inclusion criteria: * men and women 18 years or older * suspected by the out-patient flexible cystoscopy as non-muscle invasive bladder cancer. * patient who will undergo radical cystectomy. * patient with history of allergy to iodinated contrast media exclusion criteria: * refuse to complete study requirements * patient with any of the following: 1. any metallic fragment or foreign body 2. coronary and peripheral artery stents 3. aortic stent graft 4. prosthetic heart valves and annuloplasty rings 5. cardiac pacemaker 6. implanted cardioverter-defibrillator (icd) 7. retained trans venous pacemaker and defibrillator leads 8. cochlear, otologic, or other ear implant

Keywords: bladder cancer magnetic resonance imaging bladder cancer superficial
study evaluating dvs-233 sr and venlafaxine er in adult outpatients with major depressive disorder

Conditions: Major Depressive Disorder

Summary: to compare the antidepressant efficacy and safety of dvs-233 sr versus placebo in adult outpatients with mdd.


Eligibility criteria:
inclusion criteria: * outpatients. * sexually active individuals participating in the study must use a medically acceptable form of contraception during the study and for at least 15 days after the last dose of test article * subjects must have a primary diagnosis of major depressive disorder exclusion criteria: * treatment with dvs-233 sr at any time in the past * treatment with venlafaxine (immediate release \[ir\] or er) within 90 days of study day 1 * known hypersensitivity to venlafaxine (ir or er)
a study evaluating the safety, tolerability, pharmacokinetics and antiviral activity of gs-6620 in treatment naïve subjects with chronic hepatitis c virus infection

Conditions: Hepatitis C, Chronic

Summary: a double-blind, randomized, placebo-controlled, multiple dose ranging study evaluating the safety, tolerability, pharmacokinetics and antiviral activity of gs-6620 in treatment naïve subjects with chronic hepatitis c virus infection.


Eligibility criteria:
inclusion criteria: * adult subjects (18-60 years of age or up to 64 years of age with approval) * documented chronic hcv infection to be of at least 6 months duration and plasma hcv rna ≥ 5 log10 iu/ml at screening. * hcv treatment naïve * estimated creatinine clearance ≥ 80 ml/min, * qtcf interval ≤ 450 msec, qrs duration \< 100 msec, pr interval \< 220 msec, * body mass index (bmi) of 19.0 to 34.0 kg/m2, inclusive. * eligible subjects must also be hcv treatment-naïve. exclusion criteria: * subjects with prior documentation of cirrhosis, excessive current alcohol intake, any evidence of hepatocellular carcinoma (i.e., α-fetoprotein \> 50 ng/ml or by any other standard of care measure) * urine drug screen positive for illicit/illegal drugs * alt and ast levels \> 5 times the upper limit of the normal range (uln) * direct bilirubin \> uln, clinical or other laboratory evidence of hepatic decompensation (i.e., platelets \< 100,000/mm3, prothrombin time ≥ 1.5 × uln and albumin \< 3.5 g/dl) are not eligible for study participation. * subjects with an absolute neutrophil count (anc) \< 1,000 cells/mm3 (\< 750 cells/mm3 for black or african-american subjects), hemoglobin (hb) \< 11 g/dl, * coinfected with hepatitis b virus (hbv), human immunodeficiency virus (hiv), or another hcv genotype (other than type 1 for cohorts 1-5 and type 2 or 3 for cohort 6) are not eligible for study participation. * evidence of hepatocellular carcinoma * any sign of decompensated liver disease, including prothrombin time ≥ 1.5 x uln, platelets \< 100,000/mm3 or albumin \< 3.5 g/dl at screening or current or prior history of clinical hepatic decompensation (e.g., ascites, jaundice, encephalopathy or variceal hemorrhage) * history of clinically-significant illness or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol * history of a primary gastrointestinal disorder that could interfere with the absorption of the study drug or that could interfere with normal gastrointestinal anatomy or motility

Keywords: hepatitis c hcv hcv rna polymerase inhibitor treatment naïve gs-6620
complications in central american diabetic patients: historic cohort

Conditions: Diabetes Mellitus, Type 2

Summary: retrospective, observational study to determine the prevalence of complications in central american diabetic patients.

this is retrospective observational study aimed to determine the prevalence of complications in central american diabetic patients. patients included are treated in the usual outpatient practice setting and we will try to determine the prevalence of diabetic complications in these patients.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus diagnosed between 2004 and 2009 * seen by the attending physician for the first time between january and december 2009. * male or female patients between 18 and 80 years exclusion criteria: * none

Keywords: diabetes mellitus complications prevalence
stepped care treatment for common mental disorders among foreign domestic helpers

Conditions: Depression, Anxiety

Summary: the goal of this pilot randomized controlled trials is to assess the effectiveness of the stepped care approach in treating common mental disorders among foreign domestic helpers in hong kong and improve their access to evidence-based psychological treatments. participants will be required to complete an online consent form. then, around 240 eligible participants aged 18-65 years with depression (patient health questionnaire-9 \[phq-9\] ≥ 10) and/or anxiety (generalized anxiety disorder-7 \[gad-7\] ≥ 8) will be randomly assigned to the intervention and control group in a ratio of 1:1. participants assigned in the intervention group will recieved the stepped-care mental health intervention while those assigned to the control group will receive care-as-usual. assessments of depression, anxiety, and insomnia symptoms, as well as work and social adjustment, quality of life, and treatment credibility and acceptability will be conducted at baseline, week 7 (after step 1), week 14 (after step 2), week 21 (after step 3), and week 33 (12-week follow-up). an assessment of barriers to accessing care will also be collected before treatment.


Eligibility criteria:
inclusion criteria: 1. foreign domestic helpers aged 18 to 65 years; 2. able to read, write, and speak in english; 3. have a phq-9 score ≥10 and/or gad-7 ≥8, indicating caseness or a score that can be classified as a clinical case; 4. have an internet-enabled device (e.g., laptop computer, smartphone, or tablet); 5. willingness to provide informed consent and comply with the trial protocol. exclusion criteria: 1. meeting dsm-5 diagnosis of a severe mental illness including psychotic or bipolar disorders as determined by the mini international neuropsychiatric interview (mini-7); 2. having a medical condition or neurocognitive disorder that may prevent lifestyle modifications based on the research team's clinical knowledge and experience (e.g., at high risk of fall or dietary change is not suitable as recommended by physicians or dietitians); 3. current serious suicidal risk as assessed by phq-9 item 9 score \>2 (referral information to professional mental health services will be provided); 4. hospitalization or pregnancy; 5. current participation in any other clinical trial(s); 6. current psychological treatment for cmd either psychotherapy or unstable medication in the past 2 months.

Keywords: depression anxiety stepped-care model randomized controlled trial foreign domestic helpers
trial to evaluate efficacy and safety of lenabasum in diffuse cutaneous systemic sclerosis

Conditions: Diffuse Cutaneous Systemic Sclerosis

Summary: this is a phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of diffuse cutaneous systemic sclerosis (ssc). approximately 354 subjects will be enrolled in this study at about 60 sites in north america, europe, australia, and asia. the planned duration of treatment with study drug is 52 weeks.


Eligibility criteria:
key inclusion criteria: 1. ≥ 18 years of age at the time informed consent is signed. 2. diffuse cutaneous ssc (skin thickening on upper arms, upper legs, or trunk). 3. disease duration ≤ 6 years from the first non-raynaud's symptom. 4. no new or increased doses of immunosuppressive medications within 8 weeks prior to screening. key exclusion criteria: 1. unstable ssc or ssc with end-stage organ involvement at screening or visit 1. 2. any of the following values for laboratory tests at screening: 1. a positive pregnancy test in women of childbearing potential; 2. hemoglobin \< 9 g/dl for males and \< 8 g/dl for females; 3. neutrophils \< 1.0 ×10\^9/l; 4. platelets \< 75 ×10\^9/l; 5. creatinine clearance \< 50 ml/min according to the modification of diet in renal disease (mdrd) study equation; 6. aspartate aminotransferase or alanine aminotransferase \> 2.0 × upper limit of normal. 3. any medical condition or concurrent medical therapies at screening or visit 1, including a history of non-compliance with medical treatments, that may put the subject at greater safety risk, influence response to study product, or interfere with study assessments.

Keywords: scleroderma cannabinoid receptor type 2 agonist anabasum jbt-101 lenabasum
a research study to see how well cagrisema compared to tirzepatide helps people with obesity lose weight

Conditions: Obesity

Summary: this study will look at how well cagrisema compared to tirzepatide helps people lower their body weight. cagrisema is a new investigational medicine developed by novo nordisk that combines cagrilintide and semaglutide. cagrisema is not yet being prescribed by doctors. participant will get injections once a week throughout the treatment period. participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. after a first low dose, the study medicine will be gradually increased until reaching the planned dose (2.4 mg cagrisema or 15 mg tirzepatide). the study will last for about one and a half year for each participant.


Eligibility criteria:
inclusion criteria: * male or female * age 18 years or above at the time of signing the informed consent * body mass index (bmi) of ≥ 30.0 kilogram per square meter (kg/m\^2) exclusion criteria: * glycated haemoglobin (hba1c) ≥ 6.5 % (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening * history of type 1 or type 2 diabetes mellitus